Rhodojaponin VI indirectly targets Cav2.2 channels via N-ethylmaleimide-sensitive fusion protein to alleviate neuropathic pain.
Chen K, Wang T, Li Y, Wu J, Zhao CX, Liu S, Sun F, Fang Y, Hu J, Hu J, Zhang CJ, Yu H, Ma C, Yu SS.
Chen K, et al. Among authors: yu ss, yu h.
Acta Pharm Sin B. 2023 Mar;13(3):1326-1336. doi: 10.1016/j.apsb.2023.01.021. Epub 2023 Feb 3.
Acta Pharm Sin B. 2023.
PMID: 36970201
Free PMC article.